ApoGlyx is excited to announce that Anja Holm and Kenneth Stokholm are joining our Board, effective today. Anja brings deep regulatory and veterinary‑medicines expertise from her leadership atCentral VetPharma and as former Chair of EMA’s CVMP, while Kenneth brings proven commercial and operational leadership from his tenure as President & CEO of SEVER Pharma Solutions. Together they...

ApoGlyx has joined the Educate All initiative led by the United Nations Institute for Training and Research (Unitar) and microlearning platform EdApp.

The Educate All programme calls for private enterprises, institutions and thought leaders to contribute free courseware on topics important to delivering the United Nations 2030 Agenda for...

ApoGlyx is happy to announce that we have just closed a 6 million Swedish kronor investment round, coming from Almi Invest as well as from Swedish and Danish private investors. This new capitalwill allow us to progress our most advanced molecule to mandatory preclinical toxicology testing.
Furthermore, ApoGlyx has recently been accepted to READ MORE

Contributing to raising awareness about sepsis on SEPtember 13th, World Sepsis Day, four experts share their experience and opinions in a new article by Jiqing Hansen, published on Supertrends.

The CEO's of three Rising Stars Nordic Life Science Companies talk about their companies in an episode of The Scientific Podcasting Network Innovation by Innovators Series. You will hear SillaJonsdottir from Retina Risk, ApoGlyx CEO Michael Rützler, as well as Trude Tingvoll from RESPINOR.

SwedenBio, the organizer of Nordic Life Science Days, the largest Nordic partnering conference dedicated to the life science industry, today announced that APOGLYX is this year’s winner of theRising Star Award.

"Ablation of Aquaporin-9 Ameliorates the Systemic Inflammatory Response of LPS-Induced Endotoxic Shock in Mouse" has been published in Cells as part of the Special Issue Advances in Aquaporins and is available online.

Supertrends has created a dynamic report on thetopic of AQPs and sepsis. Challenges in contemporary sepsis healthcare, as well as opportunities arising from AQP based therapies are discussed, and the report presents an outlook on the...

New ApoGlyx results demonstrate that RG100204 is effective in reducing organ damage in a preclinical model of bacterial sepsis.

There is currently no specific treatment for sepsis, the body’s overreaction to infection that often causes severe organ damage, and death. According to the Global Sepsis Alliance, 47 to 50...